Senseonics Holdings, Inc., a medical technology company, designs, develops, and commercializes continuous glucose monitoring (CGM) systems for people with diabetes primarily in Europe. Its products include Eversense and Eversense XL, which are implantable CGM systems that is designed to continually and accurately measure glucose levels in people with diabetes for a period of up to 90 and 180 days. The company has a research and development license agreement with TypeZero Technologies, Inc. and Roche Diabetes Care, Inc. to develop a closed loop diabetes management system that allow users to automatically maintain tight glucose control while avoiding hypoglycemia. Senseonics Holdings, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.
Industry, Sector and Symbol
Stock Exchange NYSEAMERICAN
Industry Diagnostics & Research
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:SENS
CUSIPN/A
Phone+1-301-5157260
Debt
Debt-to-Equity Ratio0.76
Current Ratio2.93
Quick Ratio2.81
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$330,000.00
Price / Sales2,315.06
Cash FlowN/A
Price / CashN/A
Book Value($0.05) per share
Price / Book-86.80
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$-43,930,000.00
Net Margins-828.76%
Return on Equity-406.72%
Return on Assets-129.94%
Miscellaneous
Employees58
Outstanding Shares176,030,000
Market Cap$434.88 million
Senseonics (NYSEAMERICAN:SENS) Frequently Asked Questions
What is Senseonics' stock symbol?
Senseonics trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "SENS."
How were Senseonics' earnings last quarter?
Senseonics Holdings Inc (NYSEAMERICAN:SENS) announced its quarterly earnings data on Wednesday, August, 8th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.14) by $0.09. The business earned $3.62 million during the quarter, compared to analyst estimates of $3.87 million. Senseonics had a negative net margin of 828.76% and a negative return on equity of 406.72%. The company's quarterly revenue was up 345.1% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.12) EPS. View Senseonics' Earnings History.
When is Senseonics' next earnings date?
What price target have analysts set for SENS?
6 equities research analysts have issued twelve-month target prices for Senseonics' shares. Their predictions range from $5.00 to $7.00. On average, they expect Senseonics' stock price to reach $6.00 in the next twelve months. This suggests a possible upside of 38.2% from the stock's current price. View Analyst Price Targets for Senseonics.
What is the consensus analysts' recommendation for Senseonics?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Senseonics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Senseonics.
What are Wall Street analysts saying about Senseonics stock?
Here are some recent quotes from research analysts about Senseonics stock:
- 1. BTIG Research analysts commented, "Senseonics’ reported Q2 sales relatively in line with our estimates and Street expectations. That put the focus squarely on observations from the first days of US launch. Early feedback points to doctors quickly becoming comfortable with the procedure and patients enjoying a long-lasting sensor. Additionally, revenue guidance for 2018 was increased by $1M because of additional confidence in both Europe and the US. We see this as a positive following FDA approval. In our view, the only factor hindering US patient and clinician appetite for Eversense is the timing of payor coverage, which we see as an issue of when, not if. We continue to model 2018 sales slightly above the guidance range. Although SENS shares have been weak since the company’s recent financing, we think shares may trade flat to slightly up Thursday with mgmt raising expectations a bit." (8/9/2018)
- 2. Canaccord Genuity analysts commented, "We maintain our BUY rating on SENS following the FDA’s scheduling of an advisory committee (adcom panel) meeting to review Senseonics’ Eversense. The meeting is scheduled for Thursday, March 29, and comes just in time to meet management’s guidance for a Q1/18 event. As a reminder, management has guided to a US regulatory approval and commercial launch ~2 months after the adcom panel, positioning the company for a late Q2/18 launch – but we model for first US revenues in the Q3/18. We expect trading activity to increase in coming weeks in anticipation of the event, which we believe will be positive given the strong safety and efficacy data from its pivotal trial. Investment highlights The FDA announced that the Clinical Chemistry and Clinical Toxicology Devices Panel will review and make recommendations on Senseonics’ Eversense PMA submission. The adcom panel is scheduled for Thursday, March 29, 2018 and will be held in Washington DC." (3/2/2018)
Are investors shorting Senseonics?
Senseonics saw a increase in short interest in the month of August. As of August 31st, there was short interest totalling 14,340,210 shares, an increase of 3.5% from the August 15th total of 13,861,627 shares. Based on an average daily volume of 1,501,759 shares, the days-to-cover ratio is presently 9.5 days. Currently, 15.9% of the company's shares are sold short. View Senseonics' Current Options Chain.
Who are some of Senseonics' key competitors?
Some companies that are related to Senseonics include MaxCyte (MXCT), Palatin Technologies (PTN), EPIGENOMICS AG/S (EPGNY), Oncimmune (ONC), Profound Medical (PRN), Lexagene (LXG), Sernova (SVA), Co-Diagnostics (CODX), SQI Diagnostics (SQD), Parallax Health Sciences (PRLX), Cambridge Cognition (COG), LED Medical Diagnostics (LMD), 3D Signatures (DXD), GeneNews (GEN) and Deepmatter Group (DMTR).
Who are Senseonics' key executives?
Senseonics' management team includes the folowing people:
- Dr. Timothy T. Goodnow, Pres, CEO & Director (Age 56)
- Mr. R. Don Elsey, CFO, Sec. & Treasurer (Age 64)
- Dr. Mukul Jain, Chief Operating Officer (Age 45)
- Ms. Mirasol G. Panlilio, VP & Gen. Mang. of Global Commercial Operations (Age 53)
- Dr. Abhi Chavan Ph.D., VP of Engineering and R&D
Has Senseonics been receiving favorable news coverage?
News stories about SENS stock have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Senseonics earned a news impact score of 0.18 on Accern's scale. They also assigned media headlines about the company an impact score of 46.57 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days. View Recent Headlines for Senseonics.
Who are Senseonics' major shareholders?
Senseonics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (13.27%), BlackRock Inc. (2.77%), PointState Capital LP (1.94%), OppenheimerFunds Inc. (1.40%), Redmile Group LLC (0.96%) and Millennium Management LLC (0.74%). Company insiders that own Senseonics stock include Douglas A Roeder, Enterprise Associates 10 L New, Mukul Jain and Peter J Barris. View Institutional Ownership Trends for Senseonics.
Which institutional investors are selling Senseonics stock?
SENS stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC. Company insiders that have sold Senseonics company stock in the last year include Douglas A Roeder, Mukul Jain and Peter J Barris. View Insider Buying and Selling for Senseonics.
Which institutional investors are buying Senseonics stock?
SENS stock was acquired by a variety of institutional investors in the last quarter, including Gilder Gagnon Howe & Co. LLC, BlackRock Inc., PointState Capital LP, OppenheimerFunds Inc., Redmile Group LLC, Broadview Advisors LLC, Northern Trust Corp and Renaissance Technologies LLC. View Insider Buying and Selling for Senseonics.
How do I buy shares of Senseonics?
Shares of SENS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Senseonics' stock price today?
One share of SENS stock can currently be purchased for approximately $4.34.
How big of a company is Senseonics?
Senseonics has a market capitalization of $434.88 million and generates $330,000.00 in revenue each year. Senseonics employs 58 workers across the globe.
How can I contact Senseonics?
Senseonics' mailing address is 20451 Seneca Meadows Pkwy, GERMANTOWN, MD 20876-7005, United States. The company can be reached via phone at +1-301-5157260.
MarketBeat Community Rating for Senseonics (NYSEAMERICAN SENS)
MarketBeat's community ratings are surveys of what our community members think about Senseonics and other stocks. Vote "Outperform" if you believe SENS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SENS will underperform the S&P 500 over the long term. You may vote once every thirty days.
